Introduction
Mycobacterium bovis is the etiological agent of bovine tuberculosis (bTB) that infects a wide variety of mammals. M. bovis is among the causal agents of human tuberculosis. Despite the enormous efforts to control the disease, bTB is still a threat to livestock production and human health in many regions of the world. The scientific community and major livestock countries are increasingly accepting the idea that vaccination of dairy cattle would be the most efficient way to control bTB [Vordermeier et al., 2016] , especially in developing countries where the policy of test and slaughter is economically non-viable. Therefore, many vaccine candidates against bTB have been tested in cattle. However, the use of BSL3 containment for M. bovis challenge is mandatory in clinical trials with a bTB vaccine, which significantly restricts the number of vaccines to be tested. The increasing knowledge of the mechanisms involved in the interaction of M. bovis with cattle has allowed the identification of protective correlates of immunity against bTB that may facilitate the selection of vaccine candidates to be assayed in clinical trials [Waters et al., 2012] .
Effective immune responses against tuberculosis infection rely on the development of a T helper type 1 (Th1)-biased cell-mediated immune response. The adaptive T cell response involves the activation of mycobacterial-specific CD4+, CD8+, and γδ T cells by dendritic cells. The T helper type 2 (Th2) response induced by M. bovis infection counteracts Th1, suppressing cell-mediated immunity responses and increasing humoral responses as the disease progresses [Pollock and Neill, 2002] . The Th1 response is characterised by the production of interferon gamma (IFN-γ), tumour necrosis factor alpha (TNF-α), and interleukin 12 (IL-12) cytokines, while the Th2 response involves the production of IL-4, IL-5, and IL-10 cytokines. The Th1/Th2 balance of the immune response determines the progress and the outcome of the tuberculosis disease. In addition, several reports have indicated that the IL-23/IL-17 balance is crucial to the regulation of the inflammatory consequences of mycobacterial infections [Khader and Cooper, 2008] . Despite the considerable advance in the comprehension of the key processes that are involved in effective immunity against tuberculosis, there are gaps in the knowledge of the protection mechanisms against bTB that remain to be filled.
Global transcriptional analysis has been used to define the repertoire of genes expressed in host-pathogen interactions in many infectious diseases. This kind of transcriptional approach has also allowed the identification of biomarkers of disease severity in cattle infected with M. bovis . By using a global transcriptional approach, Bhuju et al. [2012] identified for the first time correlates of protection that may be used to predict bTB vaccine success.
In this study, to contribute to bTB vaccine development and investigations of protective immune mechanisms, we evaluated the changes in the gene expression profile of bovine peripheral blood mononuclear cells (PBMCs) from vaccinated cattle that were either completely protected against M. bovis challenge or showed a low level of protection.
Results and Discussion
To identify host proteins with an expression level that correlates with protection against bTB, we compared the transcriptomes of M. bovis antigen-stimulated PBMCs of calves vaccinated with 3 attenuated M. bovis strains (BCG, ΔleuBCG overexpressing Ag85B, and M. bovis strain knockout in mce2 operon [Blanco et al., 2013; Rizzi et al., 2012] ) and identified those genes whose expression correlated with protection against M. bovis challenge. The study was focussed on the analysis of gene expression variability between vaccinated/protected and vaccinated/ unprotected groups upon specific antigen stimulation. Therefore, gene expression analysis of both non-stimulated samples and non-vaccinated animals were not considered in this study. The PBMC samples were obtained in 2 previous vaccine trials [Blanco et al., 2013; Rizzi et al., 2012] , in which a low proportion of the vaccinated calves were not fully protected against M. bovis challenge, showing tuberculous lesions in lungs and/or lymph nodes (LNs). We reasoned that the day before the challenge was the most favourable time point to detect a longer lasting vaccine response within the experimental schedule for these clinical trials, and for this reason animals of both vaccine trials were blood sampled 1 day before M. bovis challenge (60 days postvaccination [dpv]). PBMCs from blood samples were PPDB stimulated and stored in Trizol at -80 ° C until use. At the end of the vaccine trials the animals were grouped based on the degree of protection, regardless of the candidate vaccine inoculated. The clinical end point to define disease severity and thus protective efficacy of a vaccine was based on the presence of macroscopic lesions in lungs, lung LNs, and head LNs. Four animals with no macroscopic lesions in the lungs, lung LNs, and head LNs composed the vaccinated/protected group. Four animals with score values of 1 for lungs (1 or 2 macroscopic lesions) and 1-3 for lung LNs (6-19 lesions) composed the vaccinated/unprotected group; these scores were the highest observed among vaccinated animals ( Table 1 ) . Only PBMC samples from the 8 selected animals were used for further analysis. All nonvaccinated animals of both vaccine trials showed significant macroscopic lesions in the lungs and LNs, indicating a very good performance on the challenging procedure used to infect the animals.
Comprehensive gene expression profiles of PBMC samples from both experimental groups were generated with 8 high-density oligonucleotide bovine arrays (Affymetrix) with 24,072 probe sets. Considering a threshold of 0.05 for the adjusted p value, 70 unique probe sets showed a significant differential expression. A total of 46 and 24 genes were either upregulated or downregulated at 60 dpv in the vaccinated/protected group compared to the vaccinated/unprotected group ( Table 2 ) . Further inspection of these differentially expressed genes revealed that many of them are related to the phosphorylation of proteins and Golgi apparatus and organelles, as revealed from a GO term enrichment analysis (see online suppl. Table 1 ; for all online suppl. material, see www.karger. com/doi/10.159/000479183).
Despite its importance, there is only one study in the literature that identifies and characterises the genes of cat-tle with an expression that correlates with protection against bTB [Bhuju et al., 2012] . This previous study identified a larger number of differentially expressed genes [Bhuju et al., 2012] compared to the results obtained here. However, the remarkable disparity between the experimental designs of their study and ours may explain the different results obtained: (i) they used massive RNA sequencing and this method has an increased specificity (low background signal) and sensitivity, a broader dynamic range, and can explore new transcripts compared to microarrays; (ii) the vaccinated/unprotected group studied here included animals with low lung pathology (few visible lesions in lungs in post-mortem examination), whereas in the Bhuju et al. [2012] study the unprotected group comprised animals with a pathology undistinguishable from unvaccinated control animals. Therefore, with fewer pathological changes between the groups, a lower number of differentially expressed genes was expected in this study. In spite of these differences, 3 genes ( PIM2 , SGOL2 , and SLC35A5 ) changed their expression levels between vaccinated/protected and vaccinated/unprotected cattle in this study and that of Bhuju et al. [2012] . Interestingly, 2 of these differentially expressed genes are involved in cellular processes.
Among the differentially expressed genes with a higher fold change (greater than ±0.8) between conditions were genes likely involved in autophagy and apoptosis ( GBP6 and HTRA4 ), cytoskeleton rearrangement ( TTLL1 and TNIK ), inflammatory response ( LTB ), T cell activation ( PDE8A ), antigen presentation ( ERAP1 ), receptors of stress ligands in immune cells ( KLRK1 ), and a lysosome protein ( AGA ). All these processes are related to the innate or adaptive immune response against tuberculosis.
GBP6 is a member of the 65-kD guanylate-binding protein (Gbp) family (Gbp1, Gbp6, Gbp7, and Gbp10). It has been postulated that this family is involved in oxidase-dependent killing and autophagy pathways in phagocytes to combat listerial or mycobacterial infection. Thus, 65-kD Gbps function to co-ordinate a potent oxidative and vesicular trafficking program to protect the host from infection [Kim et al., 2011a] .
HTRA proteins belong to a unique family of multidomain serine proteases conserved from prokaryotes to humans that participate in the degradation of abnormal periplasmic proteins. In humans, HTRA participates in the regulation of cell death, cell signalling and motility, apoptosis, and other processes [Singh et al., 2015] . Interestingly, in a fusion with Rv1196 protein, an M. tuberculosis HtrA (called Rv0125) has shown to enhance the protection conferred by BCG in M. tuberculosis -infected guinea pigs [Brandt et al., 2004] .
TNIK is a member of the germinal centre kinase family involved in cell spreading or migration through cytoskeleton organisation [Lee et al. 2017] . However, various evidence [Mahmoudi et al., 2009] suggests that TNIK participates in the regulation of the inflammatory response against Salmonella [Liu et al., 2010] and Mycobacterium [Neumann et al., 2010] .
Lymphotoxin beta (LTB) is a type II membrane protein of the TNF family that is important for innate and adap- Candidate vaccine inoculated, macroscopic lesions observed at necropsy, and classification according to protection status for cattle used in the present study. L, lungs; LLN, lung lymph nodes; HLN, head lymph nodes. Pathology scores: lung lesion scores: 0, no lesions; 1, 1 -9 lesions; 2, 10 -29 lesions; 3, 30 -99 lesions; 4, 100 -199 lesions; 5, ≥200 lesions. Total LN lesion score per animal for individual nodes: 0, no lesions; 1, 1 -19 small lesions (diameter 1 -4 mm); 2, ≥20 small lesions; 3, medium-sized lesions (diameter 5 -9 mm); 4, large lesions (diameter ≥10 mm). [Ehlers et al., 2003 ]. The killer cell lectin-like receptor subfamily K member 1 (KLRK1) is a member of the C type lectin-like receptor family that is expressed on NK cells, CD8+ T cells, γδ+ T cells, and NKT cells. KLRK1 recognises a number of inducible ligands that are major histocompatibility complex (MHC) class I-like proteins. Cellular stress, such as transformation and viral or bacterial infection, including infection with M. tuberculosis [Das et al., 2001] , can lead to the induction of KLRK1 ligands on cells. Ligand-receptor interactions can result in the activation of NK and T cells, which results in the recognition and elimination of the cell by the immune system. Some studies have shown that KLRK1 may play a role in tuberculosis. Blocking KLRK1 leads to inhibition of M. tuberculosis -specific CD8+ T cells in vitro [Rausch et al., 2006] while KLRK1 expression is upregulated by mycobacterial stimulation in vitro [Cliff et al., 2004] .
The aspartylglucosaminidase APA is a hydrolase that catalyses the final steps in the lysosomal breakdown of glycoproteins [Enomaa et al., 1992] . Despite its lysosomal location, a role for this protein during phagocytosis of intracellular pathogens has not been reported so far.
ERAP1 encodes an endoplasmic reticulum aminopeptidase 1 that plays a central role in peptide trimming, a step required for the generation of most human leukocyte antigen (HLA) class I-binding peptides. Inhibition of ERAP1 peptide trimming is a viral strategy to manipulate the host immune response. For example, human cytomegalovirus-HCMV inhibits ERAP1 expression during viral infection [Kim et al., 2011b] , which leads to the [van Meijgaarden et al., 2015] . This novel unorthodox CD8 T cell phenotype displays cytotoxic and immunoregulatory activities that can strongly inhibit the growth of M. tuberculosis in human macrophages [van Meijgaarden et al., 2015] . Therefore, the lower expression of ERAP1 in protected cattle may result in a change in the immunodominance hierarchies in favour of a protective cytotoxic T lymphocyte response. PDE8A encodes cyclic nucleotide phosphodiesterase-8. PDE families can be grouped into 3 broad categories; some are specific for cAMP hydrolysis (PDE4, PDE7, and PDE8), others are cGMP specific (PDE5, PDE6, and PDE9), and some families exhibit dual specificity (PDE1, PDE2, PDE3, PDE10, and PDE11), hydrolysing both cAMP and cGMP with different affinities. In particular, PDE8 family members are enzymes characterised by their relatively high affinity and specificity for cAMP [Soderling et al., 1998 ]. The expression of PDE8A was detected in the testes, in cardiomyocytes [Martinez et al., 2014] , and in effector CD4+ T cells [Vang et al., 2016] . In Bordetella pertussis -infected monocytes, high levels of cAMP causes the inhibition of RhoA GTPase activity and subverts phagocytic functions, decreases the capacity of dendritic cells to present soluble protein antigen to CD4+ T cells, and blocks the capacity of macrophages to kill bacteria [Kamanova et al., 2008] . In this context, low transcription of PDE8A in dendritic cells and macrophages, and in turn high levels of cAMP in vaccinated animals, does not seem to be coherent with an effective induction of a protective immune response against M. bovis . However, it has been extensively demonstrated that the expression of IFN-γ by T cells in response to a microbial pathogen, including M. tuberculosis , is dependent on a CREB (cAMP response element-binding) protein, among other factors. CREB is particularly known to bind to the IFN-γ promoter and enhances the transcription of IFN-γ by primary human T cells that are stimulated with M. tuberculosis [Samten et al., 2002 [Samten et al., , 2005 . Since cAMP is necessary for T cells to produce IFN-γ in response to M. tuberculosis and likely to M. bovis , a low level of PDE8A expression in PBMC is consistent with a more effective immune response against tuberculosis with a higher production of IFN-γ.
TTLL1 is a member of a large family of proteins with a TTL homology domain that regulates the dynamics of the microtubules by catalysing the ligations of glutamate side chains of variable lengths on tubulins. Since polyglutamylation occurs in other protein substrates and may be considered as a potential regulator of diverse cellular functions [Janke et al., 2005] there is not a clear relationship between the transcription of TTLL1 and the lack of protection against bTB.
The 10 most differentially expressed genes in the microarray experiment were assessed by RT quantitative (q) PCR ( Fig. 1 ) . The RT qPCR analysis was performed on RNA samples obtained 60 dpv from the same sets of animals used for microarrays analysis. As shown in Figure 1 , PDE8A , ERAP1 , and TTLL1 expression showed significant downregulation in the protected group, which is consistent with the microarray results. The RT qPCR data for GBP6 , TNIK , ETS1 , PRKCQ , and HTR4A genes were consistent with that of the microarray experiments but the differences were not statistically significant. In contrast to the microarray results, the expression of LTB and PIM2 was downregulated in the protected group, and differences were not statistically significant between the groups. Therefore, PDE8A , ERAP1 , and TTLL1 changed their expression between the groups (in microarray and RT qPCR experiments) irrespective of the vaccine used, which makes these genes good targets to be validated as bTB protective biomarkers. Relative gene expression between PBMCs from vaccinated/ unprotected animals ( n = 4) and vaccinated/protected animals ( n = 4) obtained by RT qPCR. The fold change was calculated using gadph mRNA expression as the reference gene and unprotected condition as the calibrator. Data were analysed using a random permutation test (fg statistical software, * p < 0.05). Bars represent the average expression ratios ± SD between the protected and unprotected conditions. Fold change
The low expression of ERAP1 and PDE8A in the context of protective immunity against tuberculosis is consistent with a possible scenario in which the non-classical MHC class I molecule HLA-E is upregulated and the production of IFN-γ is increased, respectively, representing 2 immunological events that should favour the killing of intracellular mycobacteria. In addition, the GBP6 , HTRA , TNIK , and KLRKI genes, which were upregulated in the protected group, express proteins that also participate in the immune and/or cellular responses against tuberculosis. However, their differential expression could not be confirmed by RT qPCR for the first 3 genes, probably due to the limited sample sizes and the high biological variation among animals. Therefore, the differentially expressed genes identified here would clearly assist the evaluation and characterisation of candidate vaccines. However, further validation in samples from independent experiments is required.
Experimental Procedures
Vaccine Trials and Sample Collection PBMCs were obtained from blood samples of cattle from 2 bTB vaccine trials. The animals were sampled at 60 dpv and 1 day before challenge with virulent M. bovis ( M. bovis 04-303). At the end of these vaccine trials, the animals were euthanised and necropsy was conducted paying special attention to typical tuberculous lesions [Blanco et al., 2013; Rizzi et al., 2012] . Pathology scores were determined as previously published [Wedlock et al., 2008 ] to evaluate vaccine efficacy.
PBMCs Isolation and RNA Purification
Heparinised blood (10 mL) from each animal was used for PBMC isolation by gradient centrifugation over histopaque 1077 (Sigma Aldrich, St Louis, MO, USA) following the manufacturer's protocol. Cells were stimulated in 12-well tissue culture plates with a 20-μg/mL final concentration of PPDB (Biocor Animal Health, Omaha, NE, USA) overnight (16 h) at 37 ° C [Bhuju et al., 2012] in RPMI complete medium supplemented with 10% bovine foetal serum (Internegocios, Mercedes, Buenos Aires). Total RNA was purified from 1 × 10e7 PBMCs with Trizol reagent (Thermo Fisher Scientific, Waltham, MA, USA) and RNeasy MiniElute kit (Qiagen, Hilden, Germany). The RNA quality and quantity were verified by microelectrophoresis in a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA).
Microarray Hybridisation
The Affymetrix GeneChip Bovine Genome Array platform (Affymetrix, Santa Clara, CA, USA) was used in this study. The array contains 24,027 probe sets representing over 23,000 transcripts from Bos taurus and includes approximately 19,000 annotated UniGene clusters. Each RNA sample was processed and hybridised to individual slides. Target preparation and microarray processing procedures were carried out at the Affymetrix facility of the School of Agronomy of the University of Buenos Aires, as described in the Affymetrix GeneChip expression analysis manual, and scanning was performed with a Microarray Scanner 3000 7G (Affymetrix). Eight microarrays were used in total (1 for each RNA sample).
Statistical Analysis of Microarray Data
The analysis of expression data was performed with different packages from the Bioconductor project (http://www.bioconductor.org/), an extension for bioinformatics of the R statistical language (http://www.r-project.org/). The data quality of cell intensity (CEL) files obtained from the Affymetrix chips was assessed with the affyPLM [Brettschneider et al., 2008] package. The expression data were normalised using the rma function of the package Affy [Gautier et al., 2004] , which essentially reproduces the standardisation procedure of Affymetrix MicroArray Suite (MAS) software. To filter the arrays, the genefilter package was used. Only probe sets with entries in the NCBI gene database (http://www. ncbi.nlm.nih.gov/gene) were considered, and an Anova filter was applied to remove genes with little variation between treatments or high levels of noise (cut-off = 0.055). A total of 203 probe sets passed the filtering step. The detection of probe sets with differential expression between the protected and unprotected animals was performed with linear models and empirical Bayes methods to correct for multiple comparisons as implemented in the Linear Models for Microarray Data (LIMMA) package [Smyth, 2004] . The functional analysis of differentially expressed genes was performed with the DAVID tool [Huang et al., 2009] .
Validation of Microarray Results by RT qPCR
In total, 200 ng of each RNA sample was employed for cDNA synthesis. Reverse transcription was made using SuperScrip reverse transcriptase II (Thermo Fisher Scientific). qPCR was performed in an Applied Biosystems Step One plus real-time thermocycler (Thermo Fisher Scientific) under standard cycling conditions. Specific oligonucleotides for 10 selected genes were designed using primer 3 [Untergasser et al., 2007] and employed at a final concentration of 300 n M . The primer sequences, PCR efficiencies, and the melting temperature of the amplicon are listed in online supplementary Table 2 . Reactions were carried out using Taq platinum polymerase mix (Thermo Fisher Scientific), SYBR green I (Roche, Penzberg, Germany), 1 μL of a 2-fold dilution cDNA template and primers. All reactions were performed in duplicate, and qPCR data were analysed using the 2-ΔΔCq method with efficiency correction. The amplification curves were studied using LinReg software [Ramakers et al., 2003 ]. The fold change was calculated using gapdh as the reference gene [Robinson et al., 2007] and the unprotected condition as calibrator. A permutation test developed by Pfaffl et al. [2002] and included in the fg statistic software [di Rienzo et al., 2013] was used for the statistical analysis of the data. This test uses the 2 − ΔΔCT algorithm and permutations between control and treatment samples as a method to analyse the relative changes in gene expression. The qPCR procedure was designed according to MIQE general recommendations [Bustin et al., 2009] .
